certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Nucleic acid metabolism refers to the set of chemical reactions involved in the synthesis and degradation of nucleic acids (DNA and RNA). Nucleic acids are polymers (biopolymers) composed of monomers called nucleotides. Nucleotide synthesis is an anabolic process that typically involves the chemical reaction of a phosphate group, a pentose sugar, and a nitrogenous base. In contrast, the degradation of nucleic acids is a catabolic process in which nucleotides or nucleobases are broken down, and their components can be salvaged to form new nucleotides. Both synthesis and degradation reactions require multiple enzymes to facilitate these processes. Defects or deficiencies in these enzymes can lead to a variety of metabolic disorders.
=== Period 3: final narrative evolution === The final stage at Kizil is Period 3 of the Second Indo-Iranian Style. Towards the end of its florescence, Kizil saw the emergence of the domed central pillar cave, a type of "central pillar" structure, with niche and circumambulating corridor, but with a very uncharacteristic near-cubic main cella crowned by a magnificent cupola decorated with divinities. The style of painting is very refined, and can also be seen in some other caves in the region such as in Kumtura. The iconography too has evolved, with a cosmological Buddha becoming omnipresent and majestic, often surrounded by myriads of emanations of smaller Buddhas. This exceptional and very refined type of cave is exemplified by Cave 123, the "Cave with the Ring-Bearing Doves". It represents a final narrative evolution, in which the figures of the cosmological Buddha predominate, while secondary figures and stories take an ever-smaller role.
The short half-life and limited penetrating power of alpha radiation through tissues offers advantages in situations where the "tumor burden is low and/or malignant cell populations are located in close proximity to essential normal tissues." Significant morbidity in cell culture models of human cancers has been achieved with from one to ten astatine-211 atoms bound per cell.
=== In epithelial tumors === Clear cell renal cell carcinoma (Clear cell RCC) CD10+ distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers. Chromophobe carcinoma and oncocytoma are CD10−. Pancreatic tumors Solid pseudopapillary tumours are CD10+. CD10+ differentiates mucinous cystic neoplasms (CD10+/CK20+) from intraductal papillary mucinous neoplasm of branch duct type (CD10−/CK20-). Cutaneous tumors CD10 may differentiate basal cell carcinoma (CD10 epithelial staining) from trichoblastoma (CD10 peritumoral stromal staining), basal cell carcinoma with follicular differentiation (CD10 stromal and epithelial staining) and squamous cell carcinoma (strong stromal staining). CD10 differentiates CD10+ atypical fibroxanthoma from CD10− spindle cell melanoma and sarcomatoid squamous cell carcinoma. Urothelial tumors express CD10 (42-67%). CD10 expression is strongly correlated with high tumor grade and stage in urothelial carcinoma of the bladder. CD10 may be associated with tumor progression in bladder cancer pathogenesis.
Sources: en.wikipedia.org
For example, Pseudomonas sp which is incubated for 24days decomposed 59.1% and 67.6% of crude oil at 28 °C and 36 °C respectively. In the case of Bacillus sp, it broke down each 71.4% and 77.8% of crude oil at 28 °C and 36 °C. The lowest amount of crude oil was degraded at 44 °C by Pseudomonas sp and at 20 °C by Bacillus sp. Exposure of both bacteria to the crude oil at 28 °C for 14days showed a different level of BLCO degradation depending on pH level. At pH 7.0, the largest degree of crude oil degradation was seen by Bacillus sp, while Pseudomonas sp decayed BLCO the most at pH 7.4. After its peak decomposition of crude oil, the level of degradation decreased drastically no matter how high pH was. The abilities of decomposition differ but it has proved that some bacteria in soil are capable of biodegradation of bonny light oil. Therefore, those bacteria can contribute to purifying soil that are polluted by crude oil.
Hydroxyl radicals are highly reactive and undergo chemical reactions that make them short-lived. When biological systems are exposed to hydroxyl radicals, they can cause damage to cells, including those in humans, where they can react with DNA, lipids, and proteins.
These reductions in metabolic rate and heart rate do not appear to decrease the bear's ability to heal injuries during hibernation. Their circadian rhythm stays intact during hibernation. This allows the bear to sense the changes in the day based on the ambient temperature caused by the sun's position in the sky. It has also been shown that ambient light exposure and low disturbance levels (that is to say, wild bears in ambient light conditions) directly correlate with their activity levels. The bear keeping track of the changing days allows it to awaken from hibernation at the appropriate time of year to conserve as much energy as possible. The hibernating bear does not display the same rate of muscle and bone atrophy relative to other nonhibernatory animals that are subject to long periods of inactivity due to ailment or old age. A hibernating bear only loses approximately half the muscular strength compared to that of a well-nourished, inactive human. The bear's bone mass does not change in geometry or mineral composition during hibernation, which implies that the bear's conservation of bone mass during hibernation is caused by a biological mechanism. During hibernation American black bears retain all excretory waste, leading to the development of a hardened mass of fecal material in the colon known as a fecal plug. Leptin is released into the bear's systems to suppress appetite. The retention of waste during hibernation (specifically in minerals such as calcium) may play a role in the bear's resistance to atrophy.
Centers for Disease Control and Prevention study found people treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin. Fluoroquinolones prolong the heart's QT interval by blocking voltage-gated potassium channels. Prolongation of the QT interval can lead to torsades de pointes, a life-threatening arrhythmia, but in practice, this appears relatively uncommon in part because the most widely prescribed fluoroquinolones (ciprofloxacin and levofloxacin) only minimally prolong the QT interval. In 2019 study by Journal of the American College of Cardiology it was discovered that fluoroquinolones could increase the risk for heart valve diseases. Events that may occur in acute overdose are rare, and include kidney failure and seizure. Susceptible groups of patients, such as children and the elderly, are at greater risk of adverse reactions during therapeutic use.
== Pathophysiology == Hemoglobin is a protein containing iron that facilitates the transportation of oxygen in red blood cells. Hemoglobin in the blood carries oxygen from the lungs to the other tissues of the body, where it releases the oxygen to enable metabolism. A healthy level of hemoglobin for men is between 13.2 and 16.6 grams per deciliter, and in women between 11.6 and 15 g/dl. Normal adult hemoglobin (HbA) is composed of four protein chains, two α and two β-globin chains arranged into a heterotetramer. In thalassemia, patients have defects in the noncoding region of either the α or β-globin genes, causing ineffective production of normal alpha- or beta-globin chains, which can lead to ineffective erythropoiesis, premature red blood cell destruction, and anemia. The thalassemias are classified according to which chain of the hemoglobin molecule is affected. In α-thalassemias, production of the α-globin chain is affected, while in β-thalassemia, production of the β-globin chain is affected.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.